Research progression in response evaluation of antiangiogenic therapy for advanced colorectal cancer
GU Ruidong
MA Xingqun
WANG Lin
Abstract：Antiangiogenic therapy is an important part of the treatment of malignancy such as kidney cancer, liver cancer and colorectal cancer. Unlike cytotoxic drugs that directly kill cancer cells, antiangiogenic therapy acts on tumor blood vessels and exerts anti-tumor effects by inhibiting tumor growth. Precise response evaluation of antiangiogenic therapy is challenging. New reponse evaluation criteria such as MASS criteria for renal cell carcinoma and mRECIST criteria for hepatocellualar carcinoma have been proposed and make up for the defects of RECIST to some extent. CT morphological criteria, magnetic resonance imaging, contrast enhanced ultrasound, PET/CT and circulating tumor DNA also provide new methods for response evaluation of antiangiogenic therapy for advanced colorectal cancer. This review summarizes the recent advances made in the area of response evaluation of antiangiogenic therapy for advanced colorectal cancer.
Keywords：Colorectal cancerAntiangiogenic therapyResponse evaluation
Publication Date：2019-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 81-86 )